Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. We show 21 historical shares outstanding datapoints in our PASG shares outstanding history coverage, used to compute PASG market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PASG market cap history over the course of time is important for investors
interested in comparing PASG's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PASG versus a peer is one thing; comparing
PASG market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PASG can fluctuate over the course of history.
With this page we aim to empower investors researching PASG by allowing them to research the PASG market cap history. |
Free PASG Email Alerts:
Video: The Importance of Market Cap
